Vaccine impact: Benefits for human health
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Unlike most drugs, whose benefit is restricted to the individual who takes the drug, prophylactic vaccines have the potential for far-reaching effects that encompass health service utilisation, general health and wellbeing, cognitive development and, ultimately, economic productivity. The impact of immunisation is measured by evaluating effects directly on the vaccinated individual, indirectly on the unvaccinated community (herd protection), the epidemiology of the pathogen (such as changing circulating serotypes or prevention of epidemic cycles), and the additional benefits arising from improved health. Aside from protection of the individual, the broader success of immunisation is dependent on achieving a level of coverage sufficient to interrupt transmission of the pathogen. When evaluating the cost-effectiveness of vaccines, all of these potential benefits need to be accounted for. In many countries where immunisation programmes have been highly successful, the control of disease has meant that the benefits of immunisation have become less obvious. Once a well-known and much-feared disease appears to have disappeared, individuals, including healthcare professionals, no longer view ongoing prevention with the same sense of urgency. Reduced coverage is inevitably associated with resurgence in disease, with outbreaks potentially leading to significant morbidity and loss of life. Ensuring the continued success of immunisation programmes is the responsibility of all: individuals, healthcare professionals, government and industry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Parasite prevalence and the worldwide distribution of cognitive ability
Eppig, C., Fincher, C. L., & Thornhill, R. (2010) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2010.0973 · Cited by 313 · cited 3×
“More recent work [33] suggests that the burden of disease in the population (drawn from WHO statistics) can explain much, if not all, of the observed IQ differences.”
BackgroundRetractedAn Inquiry into the Nature and Causes of the Wealth of Nations
Smith, A. (1776) · The Glasgow Edition of the Works and Correspondence of Adam Smith, Vol. 2: An Inquiry into the Nature and Causes of the Wealth of Nations, Vol. 1 · doi:10.1093/oseo/instance.00043218 · Cited by 11,757
Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold
Neumann, P. J., Cohen, J. T., & Weinstein, M. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1405158 · Cited by 2,249 · cited 1×
“This value varies from region-to-region [20], and WHO recommends that any new medical intervention can be considered as being very cost-effective if its incremental cost-effectiveness result when compared with the existing situation is below the threshold of one times the Gross Domestic Product (GDP) per capita [21].”
BackgroundFoundations of Cost-Effectiveness Analysis for Health and Medical Practices
Weinstein, M. C., & Stason, W. B. (1977) · New England Journal of Medicine · doi:10.1056/nejm197703312961304 · Cited by 2,119
"Herd Immunity": A Rough Guide
Fine, P., Eames, K., & Heymann, D. L. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir007 · Cited by 1,247
Herd Immunity: History, Theory, Practice
Fine, P. E. M. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036121 · Cited by 905
Vaccine hesitancy and healthcare providers
Paterson, P., Meurice, F., Stanberry, L. R., Glismann, S., Rosenthal, S. L., & Larson, H. J. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.10.042 · Cited by 897
Thresholds for the cost–effectiveness of interventions: alternative approaches
Marseille, E., Larson, B., Kazi, D. S., Kahn, J. G., & Rosen, S. (2015) · Bulletin of the World Health Organization · doi:10.2471/blt.14.138206 · Cited by 851
Eddy, D. M., Hollingworth, W., Caro, J. J., Tsevat, J., McDonald, K. M., & Wong, J. B. (2012) · Medical Decision Making · doi:10.1177/0272989x12454579 · Cited by 799
THE e ANTIGEN AND VERTICAL TRANSMISSION OF HEPATITIS B SURFACE ANTIGEN
BEASLEY, R. P., TREPO, C., STEVENS, C. E., & SZMUNESS, W. (1977) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112370 · Cited by 611
Eddy, D. M., Hollingworth, W., Caro, J. J., Tsevat, J., McDonald, K. M., & Wong, J. B. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.012 · Cited by 466
Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality
Mina, M. J., Metcalf, C. J. E., de Swart, R. L., Osterhaus, A. D. M. E., & Grenfell, B. T. (2015) · Science · doi:10.1126/science.aaa3662 · Cited by 421 · cited 1×
“ciently prevented by measles vaccination [86,87].”
One Century of Global IQ Gains: A Formal Meta-Analysis of the Flynn Effect (1909–2013)
Pietschnig, J., & Voracek, M. (2015) · Perspectives on Psychological Science · doi:10.1177/1745691615577701 · Cited by 316 · cited 1×
“Additionally, in both developing and developed economies it has been noted that average IQ has risen significantly over the last century (the so-called ‘‘Flynn effect”) with particularly sharp rises in average national IQ in the periods of rapid increase in national GDP associated with industrialisation; even when imp…”
BackgroundDoes the AIDS epidemic threaten economic growth?
Bloom, D. E., & Mahal, A. S. (1997) · Journal of Econometrics · doi:10.1016/s0304-4076(96)01808-8 · Cited by 283
Lieu, T. A. (2000) · JAMA · doi:10.1001/jama.283.11.1460 · Cited by 279
Incidence of Hepatitis A in Israel Following Universal Immunization of Toddlers
Dagan, R. (2005) · JAMA · doi:10.1001/jama.294.2.202 · Cited by 261
Study Designs for Dependent Happenings
Halloran, M. E., & Struchiner, C. J. (1991) · Epidemiology · doi:10.1097/00001648-199109000-00004 · Cited by 241
Tate, J. E., Panozzo, C. A., Payne, D. C., Patel, M. M., Cortese, M. M., Fowlkes, A., & Parashar, U. D. (2009) · PEDIATRICS · doi:10.1542/peds.2008-3528 · Cited by 239
Bloom, D. E., Canning, D., & Weston, M. (2017) · Fighting the Diseases of Poverty · doi:10.4324/9780203791950-8 · Cited by 238
Curns, A. T., Steiner, C. A., Barrett, M., Hunter, K., Wilson, E., & Parashar, U. D. (2010) · The Journal of Infectious Diseases · doi:10.1086/652403 · Cited by 207
Correia, J. B., Patel, M. M., Nakagomi, O., Montenegro, F. M. U., Germano, E. M., Correia, N. B., Cuevas, L. E., Parashar, U. D., Cunliffe, N. A., & Nakagomi, T. (2010) · The Journal of Infectious Diseases · doi:10.1086/649843 · Cited by 207
WHO Guide for standardisation of economic evaluations of immunization programmes
Walker, D. G., Hutubessy, R., & Beutels, P. (2010) · Vaccine · doi:10.1016/j.vaccine.2009.06.035 · Cited by 189
Glanz, J. M., McClure, D. L., Magid, D. J., Daley, M. F., France, E. K., Salmon, D. A., & Hambidge, S. J. (2009) · Pediatrics · doi:10.1542/peds.2008-2150 · Cited by 167
SHAPIRO, C. N. (1993) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199305000-00036 · Cited by 166
Plans-Rubió, P. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.18444 · Cited by 155 · cited 1×
“When the prevalence of protected individuals in a population against a person-to-person transmissible disease is higher than the herd protection threshold, the number of secondary cases per infected case is lower than one and the spread of disease is, in theory, blocked [8].”
BackgroundThe broader economic impact of vaccination: reviewing and appraising the strength of evidence
Jit, M., Hutubessy, R., Png, M. E., Sundaram, N., Audimulam, J., Salim, S., & Yoong, J. (2015) · BMC Medicine · doi:10.1186/s12916-015-0446-9 · Cited by 153 · cited 1×
“WHO concludes that vaccines have the ability to achieve broad societal or community gains more easily than any other medical intervention [38].”
BackgroundAaby, P., Kollmann, T. R., & Benn, C. S. (2014) · Nature Immunology · doi:10.1038/ni.2961 · Cited by 148
Vaccine effects and impact of vaccination programmes in post-licensure studies
Hanquet, G., Valenciano, M., Simondon, F., & Moren, A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.006 · Cited by 144
Pertussis Epidemic—California, 2014
Winter, K., Glaser, C. A., Watt, J., & Harriman, K. H. (2015) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2015.02.009 · Cited by 133
The Resurgence Of Measles In The United States, 1989-1990
ATKINSON, W. L., Orenstein, W. A., & Krugman, S. (1992) · Annual Review of Medicine · doi:10.1146/annurev.me.43.020192.002315 · Cited by 131
The role of economic evaluation in the pricing and reimbursement of medicines
Drummond, M., Jönsson, B., & Rutten, F. (1997) · Health Policy · doi:10.1016/s0168-8510(97)00901-9 · Cited by 129
Paulke‐Korinek, M., Kundi, M., Rendi‐Wagner, P., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.104 · Cited by 121
Aaby, P., Bhuiya, A., Nahar, L., Knudsen, K. M., de Francisco, A., & Strong, M. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg005 · Cited by 117
The economic value of vaccination: why prevention is wealth
Rémy, V., Largeron, N., Quilici, S., & Carroll, S. (2015) · Journal of Market Access & Health Policy · doi:10.3402/jmahp.v3.29284 · Cited by 108
Newall, A. T., Jit, M., & Hutubessy, R. C. W. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0162-x · Cited by 103
Future Infectious Disease Threats to Europe
Suk, J. E., & Semenza, J. C. (2011) · American Journal of Public Health · doi:10.2105/ajph.2011.300181 · Cited by 97
PALMU, A. A. I., Jokinen, J., Nieminen, H. P., Rinta‐Kokko, H., Ruokokoski, E., Puumalainen, T., Borys, D., Lommel, P., Traskine, M., Moreira, M., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70338-4 · Cited by 97
Economic Evaluation of Vaccination Programmes
Beutels, P., Edmunds, W. J., anzas, F. A., de Wit, G. A., Evans, D., Feilden, R., Fendrick, A. M., Ginsberg, G. M., Glick, H. A., Mast, E. E., et al. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220010-00001 · Cited by 96
Eradication versus control: the economics of global infectious disease policies.
Barrett, S. A. (2004) · Europe PMC (PubMed Central) · Cited by 83
NATIONAL IQS PREDICT DIFFERENCES IN SCHOLASTIC ACHIEVEMENT IN 67 COUNTRIES
Lynn, R., Meisenberg, G., Mikk, J., & Williams, A. (2007) · Journal of Biosocial Science · doi:10.1017/s0021932007001964 · Cited by 76
Cost and Cost-Effectiveness of Childhood Vaccination against Rotavirus in France.
Dervaux, B., Yazdanpanah, Y., Melliez, H., Lévy-Bruhl, D., Boëlle, P., & Baron, S. (2007) · HAL · Cited by 73
Childhood Survival in Haiti: Protective Effect of Measles Vaccination
Holt, E., Boulos, R., Halsey, N. A., Charles, L.-M. B. E., & Boulos, C. (1990) · PEDIATRICS · doi:10.1542/peds.85.2.188 · Cited by 68
Economic evaluation in health: saving money or improving care?
Chisholm, D., & EVANS, D. B. (2007) · Journal of Medical Economics · doi:10.3111/13696990701605235 · Cited by 67
Jit, M., & Mibei, W. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.06.084 · Cited by 63
Safety of oral poliomyelitis vaccine: results of a WHO enquiry.
Esteves, K. (1988) · Europe PMC (PubMed Central) · Cited by 61
Sagoff, M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-373932-2.00354-9 · Cited by 59
Educational Achievement and Economic Self-sufficiency in Adults After Childhood Bacterial Meningitis
Roed, C., Omland, L. H., Skinhoj, P., Rothman, K. J., Sorensen, H. T., & Obel, N. (2013) · JAMA · doi:10.1001/jama.2013.3792 · Cited by 56
Brisson, M., Laprise, J.-F., Drolet, M., Van de Velde, N., Franco, E. L., Kliewer, E. V., Ogilvie, G., Deeks, S. L., & Boily, M.-C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.06.064 · Cited by 56
Dissecting the indirect effects caused by vaccines into the basic elements
Lefebvre, C. D. S., Terlinden, A., & Standaert, B. A. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1052196 · Cited by 53
Self-citationStrain diversity plays no major role in the varying efficacy of rotavirus vaccines: An overview
Velásquez, D. E., Parashar, U. D., & Jiang, B. (2014) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2014.10.008 · Cited by 52
Demarteau, N., Breuer, T., & Standaert, B. A. (2012) · PharmacoEconomics · doi:10.2165/11591560-000000000-00000 · Cited by 45
Self-citationMethods of Model Calibration: Observations from a Mathematical Model of Cervical Cancer
Taylor, D. C. A., Pawar, V. S., Kruzikas, D. T., Gilmore, K. E., Pandya, A., Iskandar, R., & Weinstein, M. C. (2010) · PharmacoEconomics · doi:10.2165/11538660-000000000-00000 · Cited by 44
Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy
Gessner, B. D., & Feikin, D. R. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.04.019 · Cited by 42
Kabir, Z., Long, J., Reddaiah, V. P., Kevany, J. J., & Kapoor, S. K. (2003) · Europe PMC (PubMed Central) · Cited by 41
The re-emergency and persistence of vaccine preventable diseases
Borba, R., Vidal, V. M., & Moreira, L. O. (2015) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201520140663 · Cited by 37
Connolly, M. P., Topachevskyi, O., Standaert, B. A., Ortega, O., & Postma, M. J. (2012) · PharmacoEconomics · doi:10.2165/11597750-000000000-00000 · Cited by 37
Self-citationHesitancy, Trust and Individualism in Vaccination Decision-Making
Suk, J. E., Lopalco, P. L., & Celentano, L. P. (2015) · PLoS Currents · doi:10.1371/currents.outbreaks.49dba84ad4146de33706b1f131d7caa3 · Cited by 26
Kotsopoulos, N., & Connolly, M. P. (2014) · Journal of Market Access & Health Policy · doi:10.3402/jmahp.v2.23897 · Cited by 22
Talbird, S. E., Taylor, T. N., Caporale, J., Ismaila, A., & Gomez, J. A. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.06.080 · Cited by 20
Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer
Demarteau, N., & Standaert, B. A. (2010) · Journal of Medical Economics · doi:10.3111/13696998.2010.490481 · Cited by 19
Self-citationToumi, M. (2015) · Journal of Market Access & Health Policy · doi:10.3402/jmahp.v3.29204 · Cited by 10
Iwai, M., Takizawa, T., Nakayama, T., et al. (2008) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540701596003 · Cited by 8
Cited by
Increasing Vaccination: Putting Psychological Science Into Action
Brewer, N. T., Chapman, G. B., Rothman, A. J., Leask, J., & Kempe, A. (2017) · Psychological Science in the Public Interest · doi:10.1177/1529100618760521 · Cited by 1,233
Current state and challenges in developing oral vaccines
Vela Ramirez, J. E., Sharpe, L. A., & Peppas, N. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.008 · Cited by 412
COVID-19 vaccines: rapid development, implications, challenges and future prospects
Kashte, S., Gulbake, A., El-Amin III, S. F., & Gupta, A. (2021) · Human Cell · doi:10.1007/s13577-021-00512-4 · Cited by 402
Understanding modern-day vaccines: what you need to know
Vetter, V., Denizer, G., Friedland, L. R., Krishnan, J., & Shapiro, M. (2018) · Annals of Medicine · doi:10.1080/07853890.2017.1407035 · Cited by 354
Opportunities and challenges for human papillomavirus vaccination in cancer
Roden, R. B. S., & Stern, P. L. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.13 · Cited by 333
Metadata
- Authors
- Doherty, M., Buchy, P., Standaert, B., Giaquinto, C., & Prado- Cohrs, D.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 34
- Issue
- 52
- Pages
- 6707-6714
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2537851890
- Cited by
- 272
- References
- 62
- FWCI
- 15.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.